Catalyst Wire Dossier Catalyst Wire Dossier

Ametumumab

ametumumab · Shanghai Celfuture Biotech Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ametumumab, covering 2023-02-01 to 2023-02-01. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer [Phase 2]

See pricing